Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [537]
News [1570]
Articles [79]
Editorials [2]
Conferences [74]
elearning [5]

Developments in checkpoint immunotherapy

Dr James Larkin - The Royal Marsden NHS Foundation Trust, London, UK
Developments in checkpoint immunotherapy ( Dr James Larkin - The Royal Marsden NHS Foundation Trust, London, UK )
22 Sep 2016

Targetted medicine to reduce melanoma mutational burden

Prof Grant McArthur - The Royal Melbourne Hospital, Melbourne, Australia
Targetted medicine to reduce melanoma mutational burden ( Prof Grant McArthur - The Royal Melbourne Hospital, Melbourne, Australia )
22 Sep 2016

VISMO trial to treat basal cell carcinoma

Prof Axel Hauschild - University of Kiel, Kiel, Germany
VISMO trial to treat basal cell carcinoma ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )
22 Sep 2016

Checkpoint inhibitor therapy for treating melanoma

Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Checkpoint inhibitor therapy for treating melanoma ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
22 Sep 2016

Connections in cancer-host immune signalling

Dr Alan Serrels - University of Edinburgh, Edinburgh, UK
Connections in cancer-host immune signalling ( Dr Alan Serrels - University of Edinburgh, Edinburgh, UK )
14 Jul 2016

A global perspective on infections related to cancer

Dr Silvia Franceschi - IARC, Lyon, France
A global perspective on infections related to cancer ( Dr Silvia Franceschi - IARC, Lyon, France )
1 Jul 2016

Editor's ASCO 2016 Roundup

Prof Gordon McVie - ecancer Editor in Chief
Editor's ASCO 2016 Roundup ( Prof Gordon McVie - ecancer Editor in Chief )
16 Jun 2016

Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma

Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, USA
Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, USA )
6 Jun 2016

MyPathway guidance of targeted therapy based on molecular profiles

Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA
MyPathway guidance of targeted therapy based on molecular profiles ( Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA )
6 Jun 2016

5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
6 May 2016

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity

Dr Thomas Dubensky - Aduro Biotech, Berkley, USA
Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity ( Dr Thomas Dubensky - Aduro Biotech, Berkley, USA )
4 May 2016

Understanding personalised medicine - the e-learning course

Prof Gordon McVie
Understanding personalised medicine - the e-learning course ( Prof Gordon McVie )
4 May 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation